{"preliminary_commentary":{"by_channel":{"x_thread":5,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04539938\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"HER2CLIMB-04","nct_id":"NCT04539938","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=her2climb-04-nct04539938. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HER2CLIMB-04","arms":[{"description":"Tucatinib + trastuzumab deruxtecan","label":"Single Arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-03-07","type":"ACTUAL"},"conditions":["HER2 Positive Breast Cancer"],"enrollment":{"count":70,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"tucatinib","otherNames":["TUKYSA, ARRY-380, ONT-380","PF-07265792"],"type":"DRUG"},{"name":"trastuzumab deruxtecan","otherNames":["T-DXd, Enhertu, DS-8201"],"type":"DRUG"}],"last_update":"2026-03-23","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-07-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment","timeFrame":"From the first dose of study treatment until the first documented PD or before start of any new anti-cancer therapy (up to 43 months)"}],"references":[{"citation":"Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton EP. Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. Clin Breast Cancer. 2026 Aug;26(8):21-30. doi: 10.1016/j.clbc.2026.05.010. Epub 2026 Jul 10.","pmid":"42431148","type":"DERIVED"}],"start_date":{"date":"2020-12-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04539938"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/her2climb-04-nct04539938"}